Tolerx Inc. should know by the end of the year whether or not they have created one of the most significant developments in preventing or slowing Type 1 diabetes, according to a recent article published by the Boston Globe.
The company said that it has completed the enrollment of 240 patients in a clinical trial of otelixizumab, a drug that aims to help the body’s immune system to “tolerate” insulin-producing cells that it would otherwise mistakenly attack and destroy.
Type 1 diabetes is an autoimmune disease in which the body attacks its own insulin-producing cells, mistaking them for foreign cells. People need insulin, the hormone that regulates sugar in the blood. People with Type 1 diabetes need to inject the hormone into their body several times each day.
The company says it could eventually offer an eight-day course of intravenous infusions of the drug for people recently diagnosed with Type 1 diabetes. The treatment could reduce the need for daily insulin shots and helping the patients control their blood sugar levels.
To receive free news updates from Diabetes News Hound delivered straight to your Inbox, sign up here.
If you already receive the free Alerts, spread the word by telling a friend to sign up here.
